WHO/EORTC classification of cutaneous lymphomas 2005: Histological and molecular aspects

Journal of Cutaneous Pathology

Volumn 32, Issue 10, 2005, Pages 647-674

  Burg, Günter ^a   Kempf, Werner ^a,b   Cozzio, Antonio ^a   Feit, Josef ^a,c   Willemze, Rein ^d   Jaffe, Elaine S ^e   Dummer, Reinhard ^a   Berti, Emilio ^f   Cerroni, Lorenzo ^g   Chimenti, Sergio ^h   Diaz Perez, José L ⁱ   Grange, Florent ^j   Harris, Nancy L ^k   Kazakov, Dmitry V ^l   Kerl, Helmut ^g   Kurrer, Michael ^m   Knobler, Robert ⁿ   Meijer, Chris J L M ^o   Pimpinelli, Nicola ^p   Ralfkiaer, Elisabeth ^q   Russell Jones, Robin ^r   Sander, Christian ^s   Santucci, Marco ^p   Sterry, Wolfram ^t   Swerdlow, Steven H ^u   Vermeer, Maarten H ^d   Wechsler, Janine ^v   Whittaker, Sean ^r   more..

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b Kempf und Pfaltz   (Switzerland)

^c UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e NATIONAL CANCER INSTITUTE   (United States)

^f UNIVERSITY OF MILAN   (Italy)

^g UNIVERSITY OF GRAZ   (Austria)

^h SAPIENZA UNIVERSITY OF ROME   (Italy)

ⁱ HOSPITAL DE CRUCES   (Spain)

^j UNIVERSITÉ DE REIMS CHAMPAGNE ARDENNE   (France)

^k MASSACHUSETTS GENERAL HOSPITAL   (United States)

^l CHARLES UNIVERSITY   (Czech Republic)

^m UNIVERSITY HOSPITAL ZURICH   (Switzerland)

ⁿ UNIVERSITY OF VIENNA   (Austria)

^o VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^p UNIVERSITY OF FLORENCE   (Italy)

^q UNIVERSITY OF COPENHAGEN   (Denmark)

^r ST THOMAS HOSPITAL   (United Kingdom)

^s DEPARTMENT OF CARDIOLOGY   (Germany)

^t HUMBOLDT UNIVERSITY   (Germany)

^u UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^v HENRI MONDOR HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CD30 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; INTERFERON REGULATORY FACTOR 4; JANUS KINASE; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MELANOMA ANTIGEN 1; MELANOMA ANTIGEN 3; PROTEIN BCL 2; PROTEIN BCL 6; STAT4 PROTEIN; STAT5 PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

B CELL LYMPHOMA; CANCER CLASSIFICATION; CLINICAL FEATURE; COMPARATIVE GENOMIC HYBRIDIZATION; CUTANEOUS GAMMA DELTA T CELL LYMPHOMA; CYTOTOXIC T CELL LYMPHOMA; DIFFUSE LARGE B CELL LYMPHOMA; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLICULAR LYMPHOMA; GRANULOMATOUS SLACK SKIN; HISTOPATHOLOGY; HUMAN; IMMUNOPHENOTYPING; LYMPHOMATOID PAPULOSIS; LYMPHOPROLIFERATIVE DISEASE; MARGINAL ZONE B CELL LYMPHOMA; MEDLINE; MOLECULAR GENETICS; MYCOSIS FUNGOIDES; NATURAL KILLER CELL; PANNICULITIS LIKE T CELL LYMPHOMA; PERIPHERAL T CELL LYMPHOMA; REVIEW; SEZARY SYNDROME; SKIN LYMPHOMA; SYSTEMATIC REVIEW; T CELL LYMPHOMA; WORLD HEALTH ORGANIZATION;

EUROPE; HUMANS; IMMUNOPHENOTYPING; INTERNATIONAL AGENCIES; KILLER CELLS, NATURAL; LYMPHOMA; LYMPHOMA, B-CELL; LYMPHOMA, T-CELL, CUTANEOUS; SKIN NEOPLASMS; WORLD HEALTH ORGANIZATION;

EID: 28344445386     PISSN: 03036987     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0303-6987.2005.00495.x     Document Type: Review

References (214)

1. Burg G, Kempf W, Katakov DV, et al. WHO/EORTC classification of cutaneous lymphomas. In: Burg G, Katakov DV, ed. Cutaneous lymphomas. Marcel Dekker, Francis & Taylor, New York 2005.
2. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105: 3768.
3. Burg G, Jane ES, Kempf W, et al. WHO-EORTC classification of cutaneous lymphomas. In: Leboit P, Burg G, Weedon D, Sarasin A, ed. WHO books: tumors of the skin. Lyon: WHO IARC, 2005.
4. LeBoit P, Burg G, Weedon D, Sarasin A, eds. Tumors of the skin. Lyon: WHO IARC, 2005.
5. Willemze R, Kerl H, Sterry W, et al. EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood 1997; 90: 354.
6. Jaffe E, Nancy LH, Stein H, Vardiman JW, eds. Tumors of hematopoietic and lymphoid tissues. Lyon: IARC, 2001.
7. Jaffe ES, Harris NL, Diebold J, Muller-Hermelink HK. World Health Organization classification of lymphomas: a work in progress. Ann Oncol 1998; 9: S25.
8. Burg G, Kempf W, Haeffner A, et al. From inflammation to neoplasia: new concepts in the pathogenesis of cutaneous lymphomas. Recent Results Cancer Res 2002; 160: 271.
9. Burg G, Dummer R, Nestle FO, Doebbeling U, Haeffner A. Cutaneous lymphomas consist of a spectrum of nosologically different entities including mycosis fungoides and small plaque parapsoriasis. Arch Dermatol 1996; 132: 567.
10. Smoller BR, Bishop K, Glusac E, Kim YH, Hendrickson M. Reassessment of histologic parameters in the diagnosis of mycosis fungoides. Am J Surg Pathol 1995; 19: 1423.
11. Santucci M, Biggeri A, Feller AC, Massi D, Burg G. Efficacy of histologic criteria for diagnosing early mycosis fungoides: an EORTC cutaneous lymphoma study group investigation. European Organization for Research and Treatment of Cancer. Am J Surg Pathol 2000; 24: 40.
12. Pimpinelli N, Olsen EA, Santucci M, et al. Defining early mycosis fungoides. J Am Acad Dermatol 2005 in press.
13. Massone C, Kodama K, Kerl H, Cerroni L. Histopathologic features of early (patch) lesions of mycosis fungoides: a morphologic study on 745 biopsy specimens from 427 patients. Am J Surg Pathol 2005; 29: 550.
14. Santucci M, Burg G, Feller AC. Interrater and intrarater reliability of histologic criteria in early cutaneous T-cell lymphoma. An EORTC cutaneous lymphoma project group study. Dermatol Clin 1994; 12: 323.
15. Shapiro PE, Pinto FJ. The histologic spectrum of mycosis fungoides/Sezary syndrome (cutaneous T-cell lymphoma). A review of 222 biopsies, including newly described patterns and the earliest pathologic changes. Am J Surg Pathol 1994; 18: 645.
16. Guitart J, Kennedy J, Ronan S, Chmiel JS, Hsiegh YC, Variakojis D. Histologic criteria for the diagnosis of mycosis fungoides: proposal for a grading system to standardize pathology reporting. J Cutan Pathol 2001; 28: 174.
17. Lund KA, Parker CM, Norins AL, Tejada E. Vesicular cutaneous T cell lymphoma presenting with gangrene. J Am Acad Dermatol 1990; 23: 1169.
18. + immunophenotype. J Am Acad Dermatol 2005; 53: 158.
19. Mao X, Lillington D, Scarisbrick JJ, et al. Molecular cytogenetic analysis of cutaneous T-cell lymphomas: identification of common genetic alterations in Sezary syndrome and mycosis fungoides. Br J Dermatol 2002; 147: 464.
20. Karenko L, Hyytinen E, Sarna S, Ranki A. Chromosomal abnormalities in cutaneous T-cell lymphoma and in its premalignant conditions as detected by G-banding and interphase cytogenetic methods. J Invest Dermatol 1997; 108: 22.
21. van Doom R, Dijkman R, Vermeer MH, Starink TM, Willemze R, Tensen CP. A novel splice variant of the Fas gene in patients with cutaneous T-cell lymphoma. Cancer Res 2002; 62: 5389.
22. Sommer VH, Clemmensen OJ, Nielsen O, et al. In vivo activation of STAT3 in cutaneous T-cell lymphoma. Evidence for an antiapoptotic function of STAT3. Leukemia 2004; 18: 1288.
23. Navas IC, Algara P, Mateo M, et al. p16(INK4a) is selectively silenced in the tumoral progression of mycosis fungoides. Lab Invest 2002; 82: 123.
24. Navas IC, Ortiz-Romero PL, Villuendas R, et al. p16(INK4a) gene alterations are frequent in lesions of mycosis fungoides. Am J Pathol 2000; 156: 1565.
25. Zhang Q, Raghunath PN, Vonderheid E, Odum N, Wasik MA. Lack of phosphotyrosine phosphatase SHP-1 expression in malignant T-cell lymphoma cells results from methylation of the SHP-1 promoter. Am J Pathol 2000; 157: 1137.
26. Scarisbrick JJ, Woolford AJ, Calonje E, et al. Frequent abnormalities of the p15 and p16 genes in mycosis fungoides and sezary syndrome. J Invest Dermatol 2002; 118: 493.
27. Scarisbrick JJ, Mitchell TJ, Calonje E, Orchard G, Russell-Jones R, Whittaker SJ. Microsatellite instability is associated with hypermethylation of the hMLH1 gene and reduced gene expression in mycosis fungoides. J Invest Dermatol 2003; 121: 894.
28. van Doom R, Zoutman WH, Dijkman R, et al. Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73. J Clin Oncol 2005; 23: 3886.
29. Rubben A, Kempf W, Kadin ME, Zimmermann DR, Burg G. Multilineage progression of genetically unstable tumor subclones in cutaneous T-cell lymphoma. Exp Dermatol 2004; 13: 472.
30. LeBoit PE. Variants of mycosis fungoides and related cutaneous T-cell lymphomas. Semin Diagn Pathol 1991; 8: 73.
31. Kazakov DV, Burg G, Kempf W. Clinicopathological spectrum of mycosis fungoides. J Eur Acad Dermatol Venereol 2004; 18: 397.
32. Kossard S, Weller P. Pseudotumorous folliculotropic mycosis fungoides. Am J Dermatopathol 2005; 27: 224.
33. Flaig MJ, Cerroni L, Schuhmann K, et al. Follicular mycosis fungoides. A histopathologic analysis of nine cases. J Cutan Pathol 2001; 28: 525.
34. Kanno S, Niizuma K, Machida S, et al. Follicular mucinosis developing into cutaneous lymphoma. Report of two cases and review of literature and 64 cases in Japan. Acta Derm Venereol (Stockh) 1984; 64: 86.
35. van Doorn R, Scheffer E, Willemze R. Follicular mycosis fungoides, a distinct disease entity with or without associated follicular mucinosis: a clinicopathologic and follow-up study of 51 patients. Arch Dermatol 2002; 138: 191.
36. Cerroni L, Fink-Puches R, Back B, Kerl H. Follicular mucinosis: a cal reappraisal of clinicopathologic features and association with mycosis fungoides and Sezary syndrome. Arch Dermatol 2002; 138: 182.
37. Ketron LW, Goodman MH. Multiple lesions of the skin apparently of epithelial origin resembling clinically mycosis fungoides. Arch Dermatol 1931; 24: 758.
38. Woringer F, Kolopp P. Lésion érythématosquameuse polycyclique de nt-bras évoluant depuis 6 ans chez un garçonnet de 13 ans. Ann Dermatol Syphilol 1939; 10: 945.
39. Braun-Falco O, Marghescu S, Wolff HH. Pagetoide reticulose Hautarzt 1973; 24: 11.
40. Deneau DG, Wood GS, Beckstead J, Hoppe RT, Price N. Woringer-Kolopp disease (pagetoid reticulosis). Four cases with histopathologic, ultrastructural, and immunohistologic observations. Arch Dermatol 1984; 120: 1045.
41. Burg G. [Pagetoid skin infiltrates]. Pathologe 1986; 7: 199.
42. Kohler S, Rouse RV, Smoller BR. The differential diagnosis of pagetoid cells in the epidermis. Mod Pathol 1998; 11: 79.
43. Kaudewitz PBG, Stein H, Klepzig K, Mason DY, Braun-Falco O. Monoclonal antibody patterns in lymphomatoid papulosis. Dermatol Clin 1985; 3: 749.
44. Mackie RM, Turbitt ML. A case of pagetoid reticulosis bearing the T cytotoxic suppressor surface marker on the lymphoid infiltrate: further evidence that pagetoid reticulosis is not a variant of mycosis fungoides. Br J Dermatol 1984; 110: 89.
45. Haghighi B, Smoller BR, LeBoit PE, Warnke RA, Sander CA, Kohler S. Pagetoid reticulosis (Woringer-Kolopp disease): an immunophenotypic, molecular, and clinicopathologic study. Mod Pathol 2000; 13: 502.
46. Berti E, Cerri A, Cavicchini S, et al. Primary cutaneous gamma/delta T-cell lymphoma presenting as disseminated pagetoid reticulosis. J Invest Dermatol 1991; 96: 718.
47. Drillenburg P, Bronkhorst CM, van der Wal AC, Noorduyn LA, Hoekzema R, Pals ST. Expression of adhesion molecules in pagetoid reticulosis (Woringer-Kolopp disease). Br J Dermatol 1997; 136: 613.
48. LeBoit PE. Granulomatous slack skin. Dermatol Clin 1994; 12: 375.
49. Clarijs M, Poot F, Laka A, Pirard C, Bourlond A. Granulomatous slack skin: treatment with extensive surgery and review of the literature. Dermatology 2003; 206: 393.
50. + T-cell lymphoproliferative disorder with features of granulomatous slack skin disease. Br J Dermatol 2002; 147: 998.
51. LeBoit PE, Beckstead JH, Bond B, Epstein WL, Frieden IJ, Parslow TG. Granulomatous slack skin: clonal rearrangement of the T-cell receptor beta gene is evidence for the lymphoproliferative nature of a cutaneous elastolytic disorder. J Invest Dermatol 1987; 89: 183.
52. Grammatico P, Balus L, Scarpa S, et al. Granulomatous slack skin: cytogenetic and molecular analyses. Cancer Genet Cytogenet 1994; 72: 96.
53. von den Driesch P, Mielke V, Simon MJ, Staib G, Tacke J, Sterry W. ["Granulomatous slack skin" - cutaneous elastolytic lymphoma]. Hautarzt 1994; 45: 861.
54. Balus L, Manente L, Remotti D, Grammatico P, Bellocci M. Granulomatous slack skin. Report of a case and review of the literature. Am J Dermatopathol 1996; 18: 199.
55. Vonderheid EC, Bernengo MG, Burg G, et al. Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol 2002; 46: 95.
56. Imai S, Burg G, Braun FO. Mycosis fungoides and Sezary's syndrome show distinct histomorphological features. Dermatologica 1986; 173: 131.
57. Sentis HJ, Willemze R, Scheffer E. Histopathologic studies in Sezary syndrome and erythrodermic mycosis fungoides: a comparison with benign forms of erythroderma. J Am Acad Dermatol 1986; 15: 1217.
58. Kamarashev J, Burg G, Kempf W, Hess Schmid M, Dummer R. Comparative analysis of histological and immunohistological features in mycosis fungoides and Sezary syndrome. J Cutan Pathol 1998; 25: 407.
59. Buechner SA, Winkelmann RK. Sezary syndrome. A clinicopathologic study of 39 cases. Arch Dermatol 1983; 119: 979.
60. Trotter MJ, Whittaker SJ, Orchard GE, Smith NP. Cutaneous histopathology of Sezary syndrome: a study of 41 cases with a proven circulating T-cell clone. J Cutan Pathol 1997; 24: 286.
61. Haneke E. [Granulomatous Sezary syndrome with epithelial islands]. Z Hautkr 1984; 59: 951.
62. Walsh NM, Prokopetz R, Tron VA, et al. Histopathology in erythroderma: review of a series of cases by multiple observers. J Cutan Pathol 1994; 21: 419.
63. - T lymphocyte subsets in Sezary syndrome. Arch Dermatol Res 1999; 291: 307.
64. Picker LJ, Michie SA, Rott LS, Butcher EC. A unique phenotype of skin-associated lymphocytes in humans. Preferential expression of the HECA-452 epitope by benign and malignant T cells at cutaneous sites. Am J Pathol 1990; 136: 1053.
65. Harmon CB, Witzig TE, Katzmann JA, Pittelkow MR. Detection of circulating T-cells with Cd4(+) Cd7(-) immunophenotype in patients with benign and malignant lymphoproliferative dermatoses. J Am Acad Dermatol 1996; 35: 404.
66. - subset in the identification of circulating Sezary cells. Br J Dermatol 2001; 144: 125.
67. Mao X, Lillington DM, Czepulkowski B, Russell-Jones R, Young BD, Whittaker S. Molecular cytogenetic characterization of Sezary syndrome. Genes Chromosomes Cancer 2003; 36: 250.
68. Eichmuller S, Usener D, Dummer R, Stein A, Thiel D, Schadendorf D. Serological detection of cutaneous T-cell lymphoma-associated antigens. Proc Natl Acad Sci USA 2001; 98: 629.
69. Haffner AC, Tassis A, Zepter K, et al. Expression of cancer/testis antigens in cutaneous T cell lymphomas. Int J Cancer 2002; 97: 668.
70. Nikolova M, Bagot M, Boumsell L, Bensussan A. Identification of cell surface molecules characterizing human cutaneous T-cell lymphomas. Leuk Lymphoma 2002; 43: 741.
71. Lessin SR, Vowels BR, Rook AH. Th2 cytokine profile in cutaneous T-cell lymphoma. J Invest Dermatol 1995; 105: 855.
72. Mitchell TJ, Whittaker SJ, John S. Dysregulated expression of COOH-terminally truncated Stat5 and loss of IL2-inducible Stat5-dependent gene expression in Sezary Syndrome. Cancer Res 2003; 63: 9048.
73. Wang SM, Coljee VW, Pignolo RJ, Rotenberg MO, Cristofalo VJ, Sierra F. Cloning of the human twist gene: its expression is retained in adult mesodermally-derived tissues. Gene 1997; 187: 83.
74. Spicer DB, Rhee J, Cheung WL, Lassar AB. Inhibition of myogenic bHLH and MEF2 transcription factors by the bHLH protein Twist. Science 1996; 272: 1476.
75. Maestro R, Dei Tos AP, Hamamori Y, et al. Twist is a potential oncogene that inhibits apoptosis. Genes Dev 1999; 13: 2207.
76. Lai KO, Chen Y, Po HM, Lok KC, Gong K, Ip NY. Identification of the Jak/Stat proteins as novel downstream targets of EphA4 signaling in muscle: implications in the regulation of acetylcholinesterase expression. J Biol Chem 2004; 279: 13383.
77. Eriksen KW, Kaltoft K, Mikkelsen G, et al. Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells. Leukemia 2001; 15: 787.
78. van Doom R, Dijkman R, Vermeer MH, et al. Aberrant expression of the tyrosine kinase receptor EphA4 and the transcription factor twist in Sezary syndrome identified by gene expression analysis. Cancer Res 2004; 64: 5578.
79. Kari L, Loboda A, Nebozhyn M, et al. Classification and prediction of survival in patients with the leukemic phase of cutaneous T cell lymphoma. J Exp Med 2003; 197: 1477.
80. Raychaudhuri S, Sutphin PD, Chang JT, Altman RB. Basic microarray analysis: grouping and feature reduction. Trends Biotechnol 2001; 19: 189.
81. + cutaneous lymphomas. Curr Probl Dermatol 1990; 19: 132.
82. Kaudewitz P, Burg G. Lymphomatoid papulosis and Ki-1 (CD30)-positive cutaneous large cell lymphomas. Semin Diagn Pathol 1991; 8: 117.
83. Willemze R, Beljaards RC. Spectrum of primary cutaneous CD30 (Ki-1)-positive lymphoproliferative disorders. A proposal for classification and guidelines for management and treatment. J Am Acad Dermatol 1993; 28: 973.
84. Paulli M, Berti E, Rosso R, et al. CD30/Ki-1-positive lymphoproliferative disorders of the skin - clinicopathologic correlation and statistical analysis of 86 cases: a multicentric study from the European Organization for Research and Treatment of Cancer Cutaneous Lymphoma Project Group. J Clin Oncol 1995; 13: 1343.
85. Drews R, Samel A, Kadin ME. Lymphomatoid papulosis and anaplastic large cell lymphomas of the skin. Semin Cutan Med Surg 2000; 19: 109.
86. Bekkenk MW, Geelen FA, van Voorst Vader PC, et al. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood 2000; 95: 3653.
87. Macaulay WL. Lymphomatoid papulosis. A continuing self-healing eruption, clinically benign - histologically malignant. Arch Dermatol 1968; 97: 23.
88. + lymphoma. Am J Dermatopathol 1996; 18: 221.
89. Willemze R, Meyer CJ, Van VW, Scheffer E. The clinical and histological spectrum of lymphomatoid papulosis. Br J Dermatol 1982; 107: 131.
90. El Shabrawi-Caelen L, Kerl H, Cerroni L. Lymphomatoid papulosis: reappraisal of clinicopathologic presentation and classification into subtypes A, B, and C. Arch Dermatol 2004; 140: 441.
91. Burg G, Hoffmann FG, Nikolowski J, Schmoeckel C, Braun FO, Stunkel K. Lymphomatoid papulosis: a cutaneous T-cell pseudolymphoma. Acta Derm Venereol (Stockh) 1981; 61: 491.
92. Kaudewitz P, Stein H, Burg G, Mason M, Braun-Falco O. Detection of Sternberg-Reed and Hodgkin cell specific antigen on atypical cells in lymphomatoid papulosis (poster). Second International Conference on Malignant Lymphoma, Lugano, June 13-16, 1984, 1984.
93. Kadin ME. Common activated helper-T-cell origin for lymphomatoid papulosis, mycosis fungoides, and some types of Hodgkin's disease. Lancet 1985; 2: 864.
94. Kaudewitz P, Burg G, Stein H, Klepzig K, Mason DY, Braun FO. Monoclonal antibody patterns in lymphomatoid papulosis. Dermatol Clin 1985; 3: 749.
95. Burg G, Hoffmann Fezer G, Nikolowski J, Schmoeckel C, Braun Falco O, Stunkel K. Lymphomatoid papulosis: a cutaneous T-cell pseudolymphoma. Acta Derm Venereol 1981; 61: 491.
96. Kummer JA, Vermeer MH, Dukers D, Meijer CJ, Willemze R. Most primary cutaneous CD30-positive lymphoproliferative disorders have a CD4-positive cytotoxic T-cell phenotype. J Invest Dermatol 1997; 109: 636.
97. Cepeda LT, Pieretti M, Chapman SF, Horenstein MG. CD30-positive atypical lymphoid cells in common non-neoplastic cutaneous infiltrates rich in neutrophils and eosinophils. Am J Surg Pathol 2003; 27: 912.
98. + cutaneous lymphoproliferations. Blood 1998; 91: 4668.
99. Beylot-Barry M, Lamant L, Vergier B, et al. Detection of t(2;5)(p23;q35) translocation by reverse transcriptase polymerase chain reaction and in situ hybridization in CD30-positive primary cutaneous lymphoma and lymphomatoid papulosis. Am J Pathol 1996; 149: 483.
100. Sarris AH, Luthra R, Papadimitracopoulou V, et al. Long-range amplification of genomic DNA detects the t(2;5)(p23;q35) in anaplastic large-cell lymphoma, but not in other non-Hodgkin's lymphomas, Hodgkin's disease, or lymphomatoid papulosis. Ann Oncol 1997; 8: 59.
101. Gellrich S, Wernicke M, Wilks A, et al. The cell infiltrate in lymphomatoid papulosis comprises a mixture of polyclonal large atypical cells (CD30-positive) and smaller monoclonal T cells (CD30-negative). J Invest Dermatol 2004; 122: 859.
102. + large primary cutaneous T cell lymphomas. J Invest Dermatol 2003; 120: 670.
103. Gallardo F, Costa C, Bellosillo B, et al. Lymphomatoid papulosis associated with mycosis fungoides: clinicopathological and molecular studies of 12 cases. Acta Derm Venereol 2004; 84: 463.
104. Stein H, Foss HD, Durkop H, et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood 2000; 96: 3681.
105. Foss HD, Marafioti T, Stein H. [The many faces of anaplastic large cell lymphoma]. Pathologe 2000; 21: 124.
106. de Bruin PC, Beljaards RC, van Heerde P, et al. Differences in clinical behaviour and immunophenotype between primary cutaneous and primary nodal anaplastic large cell lymphoma of T-cell or null cell phenotype. Histopathology 1993; 23: 127.
107. McCluggage WG, Walsh MY, Bharucha H. Anaplastic large cell malignant lymphoma with extensive eosinophilic or neutrophilic infiltration. Histopathology 1998; 32: 110.
108. + anaplastic large-cell lymphoma. Clinicopathological study of four cases and review of the literature. Br J Dermatol 2003; 148: 580.
109. Lin JH, Lee JY. Primary cutaneous CD30 anaplastic large cell lymphoma with keratoacanthoma-like pseudocarcinomatous hyperplasia and marked eosinophilia and neutrophilia. J Cutan Pathol 2004; 31: 458.
110. +) anaplastic large cell lymphomas. Morphologic, immunohistologic, clinical-characteristics. Am J Pathol 1989; 135: 359.
111. Bijl JJ, Rieger E, van Oostreen JW, et al. HOXC4, HOXC5, and HOXC6 expression in primary cutaneous lymphoid lesions. High expression of HOXC5 in anaplastic large-cell lymphomas. Am J Pathol 1997; 151: 1067-1074.
112. Macgrogan G, Vergier B, Dubus P, et al. CD30-positive cutaneous large cell lymphomas. A comparative study of clinicopathologic and molecular features of 16 cases. Am J Clin Pathol 1996; 105: 440.
113. Gascoyne RD, Aoun P, Wu D, et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 1999; 93: 3913.
114. Kapur S, Tiemann M, Menke MA, Schubert C, Parwaresch R. The role of p53 and anaplastic lymphoma kinase genes in the progression of cutaneous CD30(+) lymphoproliferative diseases. Indian J Med Res 2005; 121: 46.
115. Thompson MA, Stumph J, Henrickson SE, et al. Differential gene expression in anaplastic lymphoma kinase-positive and anaplastic lymphoma kinase-negative anaplastic large cell lymphomas. Hum Pathol 2005; 36: 494.
116. Mehregan DA, Su WP, Kurtin PJ. Subcutaneous T-cell lymphoma: a clinical, histopathologic, and immunohistochemical study of six cases. J Cutan Pathol 1994; 21: 110.
117. Salhany KE, Macon WR, Choi JK, et al. Subcutaneous panniculitis-like T-cell lymphoma: clinicopathologic, immunophenotypic, and genotypic analysis of alpha/beta and gamma/delta subtypes. Am J Surg Pathol 1998; 22: 881.
118. Kumar S, Krenacs L, Medeiros J, et al. Subcutaneous panniculitic T-cell lymphoma is a tumor of cytotoxic T lymphocytes. Hum Pathol 1998; 29: 397.
119. Salhany KE, Cousar JB, Greer JP, Casey TT, Fields JP, Collins RD. Transformation of cutaneous T cell lymphoma to large cell lymphoma. A clinicopathologic and immunologic study. Am J Pathol 1988; 132: 265.
120. Hoque SR, Child FJ, Whittaker SJ, et al. Subcutaneous panniculitis-like T-cell lymphoma: a clinicopathological, immunophenotypic and molecular analysis of six patients. Br J Dermatol 2003; 148: 516.
121. Toro JR, Liewehr DJ, Pabby N, et al. Gamma-delta T-cell phenotype is associated with significantly decreased survival in cutaneous T-cell lymphoma. Blood 2003; 101: 3407.
122. Burg G, Dummer R, Wilhelm M, et al. A subcutaneous delta-positive T-cell lymphoma that produces interferon gamma. N Engl J Med 1991; 325: 1078.
123. Gonzalez CL, Medeiros LJ, Braziel RM, Jaffe ES. T-cell lymphoma involving subcutaneous tissue. A clinicopathologic entity commonly associated with hemophagocytic syndrome. Am J Surg Pathol 1991; 15: 17.
124. Takimoto Y, Imanaka F, Sasaki N, Nanba K, Kimura N. Gamma/delta T cell lymphoma presenting in the subcutaneous tissue and small intestine in a patient with capillary leak syndrome. Int J Hematol 1998; 68: 183.
125. Weenig RH, Ng CS, Perniciaro C. Subcutaneous panniculitis-like T-cell lymphoma: an elusive case presenting as lipomembranous panniculitis and a review of 72 cases in the literature. Am J Dermatopathol 2001; 23: 206.
126. Park SB, Cho KH, Kim CW. Subcutaneous tissue involvement of CD30-positive large cell lymphoma. J Dermatol 1998; 25: 553.
127. + nasal-type T/natural killer-cell subcutaneous panniculitic lymphoma: presentation as haemophagocytic syndrome. Br J Dermatol 1999; 141: 706.
128. Takeshita M, Okamura S, Oshiro Y, et al. Clinicopathologic differences between 22 cases of CD56-negative and CD56-positive subcutaneous panniculitis-like lymphoma in Japan. Hum Pathol 2004; 35: 231.
129. Craig AJ, Cualing H, Thomas G, Lamerson C, Smith R. Cytophagic histiocytic panniculitis - a syndrome associated with benign and malignant panniculitis: case comparison and review of the literature. J Am Acad Dermatol 1998; 39: 721.
130. Bekkenk MW, Vermeer MH, Jansen PM, et al. Peripheral T-cell lymphomas unspecified presenting in the skin: analysis of prognostic factors in a group of 82 patients. Blood 2003; 102: 2213.
131. Jaffe E, Ralfkiaer E. Subcutaneous panniculitis-like T-cell lymphoma. In: Jaffe ES, Harris NL, Stein H Vardiman JW, eds. WHO classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press, 2001, 212.
132. de Wolf-Peeters C, Achten R. Gammadelta T-cell lymphomas: a homogeneous entity? Histopathology 2000; 36: 294.
133. Jaffe ES, Krenacs L Raffeld M. Classification of cytotoxic T-cell and natural killer cell lymphomas. Semin Hematol 2003; 40: 175.
134. Arnulf B, Copie-Bergman C, Delfau-Larue MH, et al. Nonhepatosplenic gammadelta T-cell lymphoma: a subset of cytotoxic lymphomas with mucosal or skin localization. Blood 1998; 91: 1723.
135. Munn SE, McGregor JM, Jones A, et al. Clinical and pathological heterogeneity in cutaneous gamma-delta T-cell lymphoma: a report of three cases and a review of the literature. Br J Dermatol 1996; 135: 976.
136. Ralfkiaer E, Wollf-Sneedorff A, Thomsen K, Geisler C, Veilsgaard G. T-cell receptor gamma/delta-positive peripheral T-cell lymphomas presenting in the skin: a clinical, histological and immunophenotypic study. Exp Dermatol 1992; 1: 31.
137. Massone C, Chott A, Metze D, et al. Subcutaneous, blastic natural killer (NK), NK/T-cell, and other cytotoxic lymphomas of the skin: a morphologic, immunophenotypic, and molecular study of 50 patients. Am J Surg Pathol 2004; 28: 719.
138. Krenacs L, Smyth MJ, Bagdi E, et al. The serine protease granzyme M is preferentially expressed in NK-cell, gamma delta T-cell, and intestinal T-cell lymphomas: evidence of origin from lymphocytes involved in innate immunity. Blood 2003; 101: 3590.
139. Przybylski GK, Wu H, Macon WR, et al. Hepatosplenic and subcutaneous panniculitis-like gamma/delta T cell lymphomas are derived from different Vdelta subsets of gamma/delta T lymphocytes. J Mol Diagn 2000; 2: 11.
140. Avinoach I, Halevy S, Argov S, Sacks M. Gamma/delta T-cell lymphoma involving the subcutaneous tissue and associated with a hemophagocytic syndrome. Am J Dermatopathol 1994; 16: 426.
141. Berti E, Tomasini D, Vermeer MH, Meijer CJ, Alessi E, Willemze R. Primary cutaneous CD8-positive epidermotropic cytotoxic T cell lymphomas. A distinct clinicopathological entity with an aggressive clinical behavior. Am J Pathol 1999; 155: 483.
142. + cutaneous T-cell lymphoma with pagetoid epidermotropism and angiocentric and angiodestructive infiltration. Arch Dermatol 1990; 126: 801.
143. Agnarsson BA, Vonderheid EC, Kadin ME. Cutaneous T cell lymphoma with suppressor/cytotoxic (CD8) phenotype: identification of rapidly progressive and chronic subtypes. J Am Acad Dermatol 1990; 22: 569.
144. Friedmann D, Wechsler J, Delfau MH, et al. Primary cutaneous pleomorphic small T-cell lymphoma. A review of 11 cases. The French Study Group on Cutaneous Lymphomas. Arch Dermatol 1995; 131: 1009.
145. Scarabello A, Leinweber B, Ardigo M, et al. Cutaneous lymphomas with prominent granulomatous reaction: a potential pitfall in the histopathologic diagnosis of cutaneous T- and B-cell lymphomas. Am J Surg Pathol 2002; 26: 1259.
146. Kim YC, Vandersteen DP. Primary cutaneous pleomorphic small/medium-sized T-cell lymphoma in a young man. Br J Dermatol 2001; 144: 903.
147. Spencer J, Perry ME, Dunn-Walters DK. Human marginal-zone B cells. Immunol Today 1998; 19: 421.
148. Tomaszewski MM, Abbondanzo SL, Lupton GP. Extranodal marginal zone B-cell lymphoma of the skin: a morphologic and immunophenotypic study of 11 cases. Am J Dermatopathol 2000; 22: 205.
149. de la Fouchardiere A, Balme B, Chouvet B, et al. Primary cutaneous marginal zone B-cell lymphoma: a report of 9 cases. J Am Acad Dermatol 1999; 41: 181.
150. Cerroni L, Signoretti S, Hofler G, et al. Primary cutaneous marginal zone B-cell lymphoma: a recently described entity of low-grade malignant cutaneous B-cell lymphoma. Am J Surg Pathol 1997; 21: 1307.
151. Servitje O, Gallardo F, Estrach T, et al. Primary cutaneous marginal zone B-cell lymphoma: a clinical, histopathological, immunophenotypic and molecular genetic study of 22 cases. Br J Dermatol 2002; 147: 1147.
152. LeBoit PE, McNutt NS, Reed JA, Jacobson M, Weiss LM. Primary cutaneous immunocytoma. A B-cell lymphoma that can easily be mistaken for cutaneous lymphoid hyperplasia. Am J Surg Pathol 1994; 18: 969.
153. Rijlaarsdam JU, van der Putte SC, Berti E, et al. Cutaneous immunocytomas: a clinicopathologic study of 26 cases. Histopathology 1993; 23: 117.
154. de Leval L, Harris NL, Longtine J, Ferry JA, Duncan LM. Cutaneous b-cell lymphomas of follicular and marginal zone types: use of Bcl-6, CD10, Bcl-2, and CD21 in differential diagnosis and classification. Am J Surg Pathol 2001; 25: 732.
155. Hoefnagel JJ, Vermeer MH, Jansen PM, Fleuren GJ, Meijer CJ, Willemze R. Bcl-2, Bcl-6 and CD10 expression in cutaneous B-cell lymphoma: further support for a follicle centre cell origin and differential diagnostic significance. Br J Dermatol 2003; 149: 1183.
156. Child FJ, Woolford AJ, Calonje E, Russell-Jones R, Whittaker SJ. Molecular analysis of the immunoglobulin heavy chain gene in the diagnosis of primary cutaneous B cell lymphoma. J Invest Dermatol 2001; 117: 984.
157. Li C, Inagaki H, Kuo TT, Hu S, Okabe M, Eimoto T. Primary cutaneous marginal zone B-cell lymphoma: a molecular and clinicopathologic study of 24 asian cases. Am J Surg Pathol 2003; 27: 1061.
158. Streubel B, Lamprecht A, Dierlamm J, et al. T(14;18) (q32;q21) involving IGH and MALT1 is a frequent chromosomal aberration in MALT lymphoma. Blood 2003; 101: 2335.
159. Gronbaek K, Ralfkiaer E, Kalla J, Skovgaard GL, Guldberg P. Infrequent somatic Fas mutations but no evidence of Bcl10 mutations or t(11;18) in primary cutaneous MALT-type lymphoma. J Pathol 2003; 201: 134.
160. Garcia CF, Weiss LM, Warnke RA, Wood GS. Cutaneous follicular lymphoma. Am J Surg Pathol 1986; 10: 454.
161. Pimpinelli N, Santucci M, Bosi A, et al. Primary cutaneous follicular centre-cell lymphoma - a lymphoproliferative disease with favourable prognosis. Clin Exp Dermatol 1989; 14: 12.
162. Rijlaarsdam JU, Meijer CJ, Willemze R. Differentiation between lymphadenosis benigna cutis and primary cutaneous follicular center cell lymphomas. A comparative clinicopathologic study of 57 patients. Cancer 1990; 65: 2301.
163. Berti E, Alessi E, Caputo R, Gianotti R, Delia D, Vezzoni P. Reticulohistiocytoma of the dorsum. J Am Acad Dermatol 1988; 19: 259.
164. Goodlad JR, MacPherson S, Jackson R, Batstone P, White J. Extranodal follicular lymphoma: a clinicopathological and genetic analysis of 15 cases arising at non-cutaneous extranodal sites. Histopathology 2004; 44: 268.
165. Sander CA, Flaig MJ. Morphologic spectrum of cutaneous B-cell lymphomas. Dermatol Clin 1999; 17: 593.
166. Cerroni L, Arzberger E, Putz B, et al. Primary cutaneous follicle center cell lymphoma with follicular growth pattern. Blood 2000; 95: 3922.
167. Cerroni L, Volkenandt M, Rieger E, Soyer HP, Kerl H. bcl-2 protein expression and correlation with the interchromosomal 14;18 translocation in
168. Bergman R, Kurtin PJ, Gibson LE, Hull PR, Kimlinger TK, Schroeter AL. Clinicopathologic, immunophenotypic, and molecular characterization of primary cutaneous follicular B-cell lymphoma. Arch Dermatol 2001; 137: 432.
169. Mirza I, Macpherson N, Paproski S, et al. Primary cutaneous follicular lymphoma: an assessment of clinical, histopathologic, immunophenotypic, and molecular features. J Clin Oncol 2002; 20: 647.
170. Child FJ, Russell-Jones R, Woolford AJ, et al. Absence of the t(14;18) chromosomal translocation in primary cutaneous B-cell lymphoma. Br J Dermatol 2001; 144: 735.
171. Child FJ, Scarisbrick JJ, Calonje E, Orchard G, Russell-Jones R, Whittaker SJ. Inactivation of tumor suppressor genes p15(INK4b) and p16(INK4a) in primary cutaneous B cell lymphoma. J Invest Dermatol 2002; 118: 941.
172. Mao X, Lillington D, Child F, Russell-Jones R, Young B, Whittaker S. Comparative genomic hybridization analysis of primary cutaneous B-cell lymphomas: identification of common genomic alterations in disease pathogenesis. Genes Chromosomes Cancer 2002; 35: 144.
173. Hallermann C, Kaune KM, Siebert R, et al. Chromosomal aberration patterns differ in subtypes of primary cutaneous B cell lymphomas. J Invest Dermatol 2004; 122: 1495.
174. Storz MN, van de Rijn M, Kim YH, Mraz-Gernhard S, Hoppe RT, Kohler S. Gene expression profiles of cutaneous B cell lymphoma. J Invest Dermatol 2003; 120: 865.
175. Vermeer MH, Geelen FA, van Haselen CW, et al. Primary cutaneous large B-cell lymphomas of the legs. A distinct type of cutaneous B-cell lymphoma with an intermediate prognosis. Dutch Cutaneous Lymphoma Working Group. Arch Dermatol 1996; 132: 1304.
176. Kodama K, Massone C, Chott A, Metze D, Kerl H, Cerroni L. Primary cutaneous large B-cell lymphomas. Clinicopathologic features, classification, and prognostic factors in a large series of patients. Blood 2005; 106: 2491-97.
177. Joly P, Charlotte F, Leibowitch M, et al. Cutaneous lymphomas other than mycosis fungoides: follow-up study of 52 patients. J Clin Oncol 1991; 9: 1994.
178. Paulli M, Viglio A, Vivenza D, et al. Primary cutaneous large B-cell lymphoma of the leg: histogenetic analysis of a controversial clinicopathologic entity. Hum Pathol 2002; 33: 937.
179. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 1937.
180. Sundram U, Kim Y, Mraz-Gernhard S, Hoppe R, Natkunam Y, Kohler S. Expression of the bcl-6 and MUM1/IRF4 proteins correlate with overall and disease-specific survival in patients with primary cutaneous large B-cell lymphoma: a tissue microarray study. J Cutan Pathol 2005; 32: 227.
181. Gronbaek K, Moller PH, Nedergaard T, et al. Primary cutaneous B-cell lymphoma: a clinical, histological, phenotypic and genotypic study of 21 cases. Br J Dermatol 2000; 142: 913.
182. Geelen FA, Vermeer MH, Meijer CJ, et al. bcl-2 protein expression in primary cutaneous large B-cell lymphoma is site-related. J Clin Oncol 1998; 16: 2080.
183. Wechsler J, Bagot M. Primary cutaneous large B-cell lymphomas. Semin Cutan Med Surg 2000; 19: 130.
184. Hoefnagel JJ, Dijkman R, Basso K, et al. Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling. Blood 2005; 105: 3671.
185. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA 2003; 100: 9991.
186. Uranishi M, Iida S, Sanda T, et al. Multiple myeloma oncogene 1 (MUM1)/interferon regulatory factor 4 (IRF4) upregulates monokine induced by interferon-gamma (MIG) gene expression in B-cell malignancy. Leukemia 2005; 19: 1471-8.
187. Muris JJ, Cillessen SA, Vos W, et al. Immunohistochemical profiling of caspase signaling pathways predicts clinical response to chemotherapy in primary nodal diffuse large B-cell lymphomas. Blood 2005; 105: 2916.
188. Ramsay AD, Smith WJ, Isaacson PG. T-cell-rich B-cell lymphoma. Am J Surg Pathol 1988; 12: 433.
189. Dommann SN, Dommann SC, Zimmerman D, Dours ZM, Hassam S, Burg G. Primary cutaneous T-cell-rich B-cell lymphoma. A case report with a 13-year follow-up. Am J Dermatopathol 1995; 17: 618.
190. Kamarashev J, Dummer R, Schmidt MH, Kempf W, Kurrer MO, Burg G. Primary cutaneous T-cell-rich B-cell lymphoma and Hodgkin's disease in a patient with Gardner's syndrome. Dermatology 2000; 201: 362.
191. Pfleger L, Tappeiner J. Zur Kenntnis der systemisierten Endotheliomatose der cutanen Blutgefaesse (Reticuloendotheliomatose?). Hautarzt 1959; 10: 359.
192. Lazova R, Slater C, Scott G. Reactive angioendotheliomatosis. Case report and review of the literature. Am J Dermatopathol 1996; 18: 63.
193. McMenamin ME, Fletcher CD. Reactive angioendotheliomatosis: a study of 15 cases demonstrating a wide clinicopathologic spectrum. Am J Surg Pathol 2002; 26: 685.
194. Ferreri AJ, Campo E, Seymour JF, et al. Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the 'cutaneous variant'. Br J Haematol 2004; 127: 173.
195. Perniciaro C, Winkelmann RK, Daoud MS, Su WP. Malignant angioendotheliomatosis is an angiotropic intravascular lymphoma. Immunohistochemical, ultrastructural, and molecular genetics studies. Am J Dermatopathol 1995; 17: 242.
196. Wick MR, Rocamora A. Reactive and malignant " angioendotheliomatosis": a discriminant clinicopathological study. J Cutan Pathol 1988; 15: 260.
197. Khoury H, Lestou VS, Gascoyne RD, et al. Multicolor karyotyping and clinicopathological analysis of three intravascular lymphoma cases. Mod Pathol 2003; 16: 716.
198. Khalidi HS, Brynes RK, Browne P, Koo CH, Battifora H, Medeiros LJ. Intravascular large B-cell lymphoma: the CD5 antigen is expressed by a subset of cases. Mod Pathol 1998; 11: 983.
199. Yegappan S, Coupland R, Arber DA, et al. Angiotropic lymphoma: an immunophenotypically and clinically heterogeneous lymphoma. Mod Pathol 2001; 14: 1147.
200. Kanda M, Suzumiya J, Ohshima K, Tamura K, Kikuchi M. Intravascular large cell lymphoma: clinicopathological, immuno-histochemical and molecular genetic studies. Leuk Lymphoma 1999; 34: 569.
201. Kanda M, Suzumiya J, Ohshima K, et al. Analysis of the immunoglobulin heavy chain gene variable region of intravascular large B-cell lymphoma. Virchows Arch 2001; 439: 540.
202. + anaplastic large cell lymphoma. Genes Chromosomes Cancer 2003; 37: 176.
203. Au WY, Shek WH, Nicholls J, Tse KM, Todd D, Kwong YL. T-cell intravascular lymphomatosis (angiotropic large cell lymphoma): association with Epstein-Barr viral infection. Histopathology 1997; 31: 563.
204. Au WY, Shek TW, Kwong YL. Epstein-Barr virus-related intravascular lymphomatosis. Am J Surg Pathol 2000; 24: 309.
205. Sepp N, Schuler G, Romani N, et al. "Intravascular lymphomatosis" (angioendotheliomatosis): evidence for a T-cell origin in two cases. Hum Pathol 1990; 21: 1051.
206. Ferry JA, Harris NL, Picker LJ, et al. Intravascular lymphomatosis (malignant angioendotheliomatosis). A B-cell neoplasm expressing surface homing receptors. Mod Pathol 1988; 1: 444.
207. Ponzoni M, Arrigoni G, Gould VE, et al. Lack of CD 29 (beta1 integrin) and CD 54 (ICAM-1) adhesion molecules in intravascular lymphomatosis. Hum Pathol 2000; 31: 220.
208. Tsukadaira A, Okubo Y, Ogasawara H, et al. Chromosomal aberrations in intravascular lymphomatosis. Am J Clin Oncol 2002; 25: 178.
209. Abe S, Kumanishi T. [Molecular genetic analysis of intravascular malignant lymphomatosis cells]. Rinsho Shinkeigaku 1995; 35: 1473.
210. + precursor cells related to plasmacytoid monocytes. Am J Surg Pathol 2002; 26: 852.
211. + lymphoma. Arch Dermatol 1996; 132: 550.
212. + hematodermic/hematolymphoid malignancy. J Am Acad Dermatol 2001; 44: 231.
213. Khoury JD, Medeiros LJ, Manning JT, Sulak LE, Bueso-Ramos C, Jones D. CD56(+) TdT(+) blastic natural killer cell tumor of the skin: a primitive systemic malignancy related to myelomonocytic leukemia. Cancer 2002; 94: 2401.
214. Gillot X. Thèse pour le doctorat en médecine. Etude surune affection de la peau décrite sous le nom de Mycosis fongoïde, 1869.